Mandel Sher

1.4k total citations
40 papers, 581 citations indexed

About

Mandel Sher is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services. According to data from OpenAlex, Mandel Sher has authored 40 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 21 papers in Physiology and 12 papers in Emergency Medical Services. Recurrent topics in Mandel Sher's work include Respiratory and Cough-Related Research (27 papers), Voice and Speech Disorders (15 papers) and Pediatric health and respiratory diseases (12 papers). Mandel Sher is often cited by papers focused on Respiratory and Cough-Related Research (27 papers), Voice and Speech Disorders (15 papers) and Pediatric health and respiratory diseases (12 papers). Mandel Sher collaborates with scholars based in United States, United Kingdom and Japan. Mandel Sher's co-authors include John A. Smith, Milton H. Paul, Edgar A. Newfeld, Hisashi Nikaidoh, Gail Dunkel Cawkwell, Robert A. Good, Sami L. Bahna, Zhi Jin Xu, Lorcan McGarvey and Alyn H. Morice and has published in prestigious journals such as The Journal of Immunology, Neurology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Mandel Sher

37 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mandel Sher United States 11 298 222 107 97 86 40 581
L. Swiader France 13 129 0.4× 105 0.5× 157 1.5× 103 1.1× 163 1.9× 60 688
B Fregonese Italy 11 234 0.8× 119 0.5× 136 1.3× 27 0.3× 33 0.4× 24 378
Leon M. van den Toorn Netherlands 15 750 2.5× 626 2.8× 83 0.8× 46 0.5× 22 0.3× 24 916
Spyridon Papiris Greece 14 414 1.4× 208 0.9× 44 0.4× 72 0.7× 36 0.4× 41 607
Valentina De Angelis Italy 12 59 0.2× 55 0.2× 37 0.3× 24 0.2× 136 1.6× 45 407
Richard Philipson United Kingdom 6 414 1.4× 268 1.2× 157 1.5× 10 0.1× 424 4.9× 11 785
Sumru Beder Türkiye 12 220 0.7× 125 0.6× 99 0.9× 70 0.7× 37 0.4× 28 428
A Talbot United States 6 144 0.5× 85 0.4× 273 2.6× 58 0.6× 13 0.2× 12 482
A Hartkamp Netherlands 14 54 0.2× 140 0.6× 65 0.6× 63 0.6× 238 2.8× 19 661
Ji Won Min South Korea 11 63 0.2× 85 0.4× 112 1.0× 38 0.4× 45 0.5× 51 430

Countries citing papers authored by Mandel Sher

Since Specialization
Citations

This map shows the geographic impact of Mandel Sher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mandel Sher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mandel Sher more than expected).

Fields of papers citing papers by Mandel Sher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mandel Sher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mandel Sher. The network helps show where Mandel Sher may publish in the future.

Co-authorship network of co-authors of Mandel Sher

This figure shows the co-authorship network connecting the top 25 collaborators of Mandel Sher. A scholar is included among the top collaborators of Mandel Sher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mandel Sher. Mandel Sher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, John A., Surinder S. Birring, Michael S. Blaiss, et al.. (2025). Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE). American Journal of Respiratory and Critical Care Medicine. 211(6). 1038–1048. 4 indexed citations
2.
Mahdavinia, Mahboobeh, Jill A. Poole, Mandel Sher, et al.. (2025). Multicenter questionnaire study investigating characteristics of adults with unexplained chronic cough versus explained chronic cough. Allergy and Asthma Proceedings. 46(5). 422–430.
3.
Bali, Vishal, Jonathan Schelfhout, Mandel Sher, et al.. (2024). Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis. Therapeutic Advances in Respiratory Disease. 18. 2693815353–2693815353. 8 indexed citations
4.
Nguyen, Allison Martin, Carmen La Rosa, Alexandra G. Cornell, et al.. (2024). Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study. Therapeutic Advances in Respiratory Disease. 18. 2693853589–2693853589. 3 indexed citations
5.
Dicpinigaitis, Peter V., Alyn H. Morice, John A. Smith, et al.. (2023). Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study. Lung. 201(3). 255–266. 24 indexed citations
6.
McGarvey, Lorcan, John A. Smith, Surinder S. Birring, et al.. (2023). Response in Patient-reported Cough Severity in Soothe, a Phase 2b Trial of Camlipixant in Refractory Chronic Cough. A2533–A2533. 5 indexed citations
7.
McGarvey, Lorcan, Mandel Sher, Susan Lu, et al.. (2023). The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough. Lung. 201(2). 111–118. 21 indexed citations
8.
McGarvey, Lorcan, John A. Smith, Alyn H. Morice, et al.. (2022). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung. 201(1). 25–35. 29 indexed citations
9.
Smith, John A., Alyn H. Morice, Lorcan McGarvey, et al.. (2022). Improvements in Cough Severity and Quality of Life in SOOTHE, A Phase 2b, Dose Finding Trial of BLU-5937 in Refractory Chronic Cough. A5608–A5608. 2 indexed citations
10.
Morice, Alyn H., Surinder S. Birring, John A. Smith, et al.. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung. 199(2). 121–129. 28 indexed citations
11.
Birring, Surinder S., John A. Smith, Alyn H. Morice, et al.. (2021). Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC). OA1199–OA1199. 4 indexed citations
12.
Smith, John A., Michael M. Kitt, P. Butera, et al.. (2020). Gefapixant in two randomised dose-escalation studies in chronic cough. European Respiratory Journal. 55(3). 1901615–1901615. 97 indexed citations
13.
Sher, Mandel, et al.. (2020). Asplenia and Hyposplenism. Immunology and Allergy Clinics of North America. 40(3). 471–483. 7 indexed citations
14.
Sher, Mandel, Gary C. Steven, Gary C. Pien, et al.. (2019). EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps. Rhinology Journal. 0(0). 0–0. 24 indexed citations
15.
Smith, John A., Elizabeth Ballantyne, Lorcan McGarvey, et al.. (2019). Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial. PA600–PA600. 8 indexed citations
16.
Sher, Mandel, Eric A. Mair, John Messina, et al.. (2017). EXHANCE-3: A Phase 3, Three-Month Study of Safety and Efficacy of Fluticasone Propionate Exhalation Delivery System (FLU-EDS) in Patients with Chronic Rhinosinusitis with (CRSwNP) and without Nasal Polyps (CRSsNP). Journal of Allergy and Clinical Immunology. 139(2). AB66–AB66. 7 indexed citations
17.
Sher, Mandel, et al.. (2001). Severe food allergies by skin contact. Annals of Allergy Asthma & Immunology. 86(5). 583–586. 56 indexed citations
18.
Sher, Mandel, et al.. (1999). Diversity in presenting manifestations of systemic lupus erythematosus in children. The Journal of Pediatrics. 135(4). 500–505. 70 indexed citations
19.
Barron, Karyl S., Mandel Sher, & E D Silverman. (1992). Intravenous immunoglobulin therapy: magic or black magic.. PubMed. 33. 94–7. 34 indexed citations
20.
Newfeld, Edgar A., Mandel Sher, Milton H. Paul, & Hisashi Nikaidoh. (1976). Pulmonary vascular disease in complete atrioventricular canal defect. The American Journal of Cardiology. 37(1). 159–159. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Swiader Breakdown of academic impact, for papers by B Fregonese Breakdown of academic impact, for papers by Leon M. van den Toorn Breakdown of academic impact, for papers by Spyridon Papiris Breakdown of academic impact, for papers by Valentina De Angelis Breakdown of academic impact, for papers by Richard Philipson Breakdown of academic impact, for papers by Sumru Beder Breakdown of academic impact, for papers by A Talbot Breakdown of academic impact, for papers by A Hartkamp Breakdown of academic impact, for papers by Ji Won Min
Rankless by CCL
2026